Vaccines that are in the developmental stages

Merck & Co, Inc.    Glaxo Wellcome-GlaxoSmithkline Beecham    Berna Products

Aventis Pasteur, Inc, Ltd, SA, Aventis Behring, LLC    Crucell     Wyeth Laboratories

   MedImmune    BioPort Corp    Chiron Behring GmbH & Co     

Evans Vaccine      Lederle Lab Div-American Cyanamid Co    Acambis      

Ross Products Division-Abbott Laboratories, Inc.    Powderject    Ipsen Limited

Massachusetts Public Health Biologic Lab    North American Vaccine, Inc

Organon Teknika Corp    AVAX Technologies, Inc.    Medeva Pharma Ltd,/Celltech

Avant Immunotherapeutics Inc.    DVC-DynPort Vaccine Company LLC    Bavarian Nordic

VaxGen    Nabi Biopharmaceuticals    Novavax    MediGene    Xenova    Protein Sciences

Immune Response Corporation     Vaxin Inc.     Oxford BioMedica     GenVec Inc.

         General Info





Merck & Co, Inc.    



Glaxo Wellcome-GlaxoSmithkline Beecham  


GlaxoSmithKline Vaccine Pipeline

Hepatitis Vaccines:
Hepatitis E - recombinant - hepatitis E prophylaxis PhaseII
Fendrix Extra Strength hepatitis B - recombinant - extra strength hepatitis B prophylaxis (pre-hemodialysis and hemodialysis patients) Submitted May 03

Paediatric Vaccines:
N. meningitidis combinations - conjugated - meningitis prophylaxis Phase II
Priorix-Tetra (MMR-varicella) - live attenuated - measles, mumps, rubella and varicella prophylaxis Phase III
Rotarix - live attenuated - oral rotavirus prophylaxis Phase III
Streptorix - conjugated - S. pneumoniae disease prophylaxis for children Phase III

Other Vaccines:
Dengue fever - attenuated tetravalent vaccine - prophylactic use Phase I
HIV - recombinant - HIV prophylaxis Phase I
New influenza - subunit - influenza prophylaxis - new delivery Phase I
S. pneumoniae elderly - recombinant - S. pneumoniae disease prophylaxis Phase I
Varicella Zoster - recombinant - Varicella Zoster prevention Phase I
Cervarix - recombinant - prophylaxis of human papillomavirus (HPV) infections Phase II
Epstein-Barr virus (EBV) - recombinant - EBV prophylaxis Phase II
Mosquirix - recombinant - malaria prophylaxis Phase II
Staphylococcal antibodies - monoclonal - antibody prevention of staphylococcal infections Phase II
Simplirix - recombinant - genital herpes prophylaxis Phase III
Boostrix Polio - subunit - adolescent/adult booster for diphtheria, tetanus, pertussis and polio Submitted Jul03
Boostrix - subunit - adolescent/adult booster for diphtheria, tetanus and pertussis Approved

Berna Products



Aventis Pasteur, Inc, Ltd, SA, Aventis Behring, LLC   

Aventis Pipeline

Key Compounds in Late-Stage Clinical Development:
Alvesco - Asthma Submitted
Apidra (insulin glulisine) - Type 1 and 2 diabetes - Submitted
Genasense - Malignant melanoma - Submitted
Menactra - Meningococcal meningitis (vaccine) - Submitted
Adacel Booster vaccine - BLA - Submitted
Exubera - Type 1 and 2 diabetes - Phase III
Pentacel - Pediatric combination vaccine - Phase III
Teriflunomide - Multiple sclerosis - Phase III
109,881 (new taxoid) - Breast cancer - Phase III
Otamixaban (0673) - Acute coronary syndrome - Phase IIb
100,907 - Sleep disturbance Phase - IIb
AVE-7688 - Hypertension; diabetic nephropathy - Phase IIb
Pralnacasan (on hold) - Rheumatoid arthritis - Phase IIb

Early-stage pipeline (phase I/II) includes the following key projects:
AVE-8062 - Cancer
VEGF Trap - Cancer; Age-related Macular Degeneration
ALVAC-CEA vaccine - Colorectal tumors
ALVAC-gp100 vaccine - Melanoma
ALVAC-HIV vaccine - HIV
Dengue vaccine - Dengue fever and dengue hemorrhagic fever
RSV vaccine - Respiratory viral infections
Pralnacasan (on hold) - Osteoarthritis and psoriasis
AVE-3933 - Alzheimer's disease
HP-184 - Spinal cord injury
NV1FGF - Peripheral vascular disease
Anti-inflammatory compounds - Asthma
PPAR agonists - Diabetes
AVE-0010 - Diabetes
Antiobesics - Obesity
Guanylate cyclase activators - Angina
BARI - Metabolism (hypercholesteremia)
SERM 3471 - Postmenopausal osteoporosis


Crucell Pipeline

Ebola Vaccine
Influenza Vaccine
Malaria Vaccine
West Nile Vaccine


Wyeth Laboratories   

Wyeth Product Pipeline

Tygacil™-(tigecycline) - is being developed as an injectable antibiotic for treating serious polymicrobic infections in hospitalized patients when resistant pathogens are known or suspected.
Pneumococcal Conjugate Vaccines - Wyeth is evaluating new pneumococcal conjugate vaccines



MedImmune Pipeline

Infectious Disease:
Epstein Barr Virus vaccine
Pneumoccocal vaccine
hMPV/PIV-3/RSV vaccine

HPV cervical cancer vaccine
Ethyol: mucositis
VitaxinTM: melanoma
VitaxinTM: prostate
Ethyol: AML
MT-103 non-Hodgkin's lymphoma
Siplizumab: T-cell lymphoma
EphA2 MAb
EphA4 MAb

IL-9 MAb


BioPort Corp   



 Chiron Behring GmbH & Co

Chiron Vaccine Pipeline

Meningococcal Disease:
Menjugate® for meningococcal C disease (US)
Geography-specific meningococcal B vaccine (New Zealand)
Broad-coverage meningococcal B vaccine
Multivalent (ACYW) meningococcal vaccine

Viral Infection:
HCV vaccine in collaboration with CSL Ltd.
HCV vaccine in collaboration with St. Louis University
HIV vaccine in collaboration with the NIH
Flu cell culture for influenza
Intranasal flu vaccine


Evans Vaccine    



Lederle Lab Div-American Cyanamid Co   




Acambis Pipeline

Smallpox: Modified Vaccinia Ankara (MVA) and vaccinia immune globulin (VIG)
ChimeriVax-West Nile
ARILVAX™-Yellow Fever
ChimeriVax-JE-Japanese encephalitis
C. difficile


Ross Products Division-Abbott Laboratories, Inc.    






Ipsen Limited



Massachusetts Public Health Biologic Lab  



 North American Vaccine, Inc



Organon Teknika Corp   

Organon Pipeline

Reproductive medicine:
Org 36286: phase II, long-acting FSH as controlled ovarian stimulation in IVF/ICSI and in ovulation induction treatment for infertility
Org 33628: phase II, progestagen/antiprogestogen combination as female contraceptive
Male contraception: phase II, progestagen/androgen combination as a male hormonal method
Livial (USA)
Implanon (USA)

Org 34517: phase II, hypothalamus-pituitary-adrenal axis modulator for the treatment of depression
Org 24448: phase II, AMPakine for the treatment of psychosis by stimulation of the brain's glutamatergic system
Org 50081: phase II, serotonin-2-blocker for the treatment of sleep disorders
asenapine: phase III, dopamine-serotonin antagonist for the treatment of psychosis

Org 25969: phase II, neuromusclular binding agent for the reversal of neuromuscular block


Org 39141: proof of concept, an auto-antigen for the treatment of rheumatoid arthritis (phase IIA)
Org 37663: phase IIA, a immunomodulatory steroid for the treatment for rheumatoid arthritis


AVAX Technologies, Inc.    



Medeva Pharma Ltd,/Celltech

Celltech Pipeline

CDP 791 - Anti-GFR antibody fragment - Cancer - Phase I
CDP 860 - Anti-PDGF beta-receptor antibody fragment - Cancer - Phase II
CMC-544 - Antibody-calicheamicin conjugate Non-Hodgkin's lymphoma - Partner: Wyeth - Phase I

Immune and Inflammatory:
CDP 323 - Alpha4 integrin antagonist - Inflammatory disease - Phase I
CDP 484 - Anti-IL-1beta fragment - Inflammatory disease - Preclinical
CDP 870 - Anti-TNFalpha antibody fragment - Rheumatoid Arthritis - Phase III
CDP 870 - Anti-TNFalpha antibody fragment - Crohn's disease - Phase III
PDE4 - PDE-4 Inhibitor - Asthma, COPD - Partner: Merck - Phase I

CDP 923 - Inherited storage disorders - Phase I
Zavesca - Gaucher's Disease Partner: Actelion / Teva - Approved


Avant Immunotherapeutics Inc.    

Avant Immunotherapeutics Pipeline

Viral Vaccines:
Rotarix®, developed in collaboration with GlaxoSmithKline
HIV-Therapore®, partnered with the U.S. Army

Bacterial Vaccines:
Typhoid Fever
ETEC - E. coli

Biodefense Vaccines:
Injectable Anthrax vaccine
Oral Anthrax/Plague Combination
Oral Anthrax


DVC-DynPort Vaccine Company LLC    

DynPort Products:
Anthrax Vaccine (rPA)
Botulinum Multivalent Vaccine (rBoT)
Botulinum Polyclonal Anti-toxin
Plague Vaccine (F1-V)
Staphylococcal Enterotoxin Vaccine (rSEB)
Tularemia Vaccine
Smallpox Vaccine
Vaccinia Immune Globulin (VIG)
Venezuelan Equine Encephalitis (VEE) Vaccine


Bavarian Nordic

Smallpox Vaccines:
* Ordered by governments as vaccines in development.

HIV Vaccines:
MVA-BN HIV Polytope
MVA-BN HIV Multiantigen

Japanese Encephalitis Vaccine:

Dengue Fever Vaccine:



VaxGen Products

rPA102: VaxGen's Anthrax Vaccine
LC16m8: VaxGen's Attenuated Smallpox Vaccine


 Nabi Biopharmaceuticals   

Nabi Biopharmaceuticals Pipeline

StaphVAX®-Staphylococcus aureus Polysaccharide Conjugate Vaccine
Altastaph™-Staphylococcus aureus Immune Globulin Intravenous (Human)
NicVAX™-Nicotine Conjugate Vaccine
Civacir™-Hepatitis C Immune Globulin (Human)
Nabi-HB® Intravenous-Hepatitis B Immune Globulin
HEBIG™ (Europe)-Hepatitis B Immune Globulin

Nabi Biopharmaceuticals begins human testing of novel vaccine to fight nicotine addiction



Novavax Vaccine Technologies

Human Papilloma Virus vaccine/therapeutic - recombinant HPV-16 L1 virus-like particle (VLP) vaccine in phase II/III clinical development and HPV-16 chimeric VLP vaccine in pre-clinical development with the National Cancer Institute (NCI) and King Pharmaceuticals;

Hepatitis E vaccine - recombinant HEV ORF2 antigen as vaccine in Phase II clinical development with the National Institute of Allergy and Infectious Diseases (NIAID), Walter Reed Army Institute for Research, and Glaxo Smith Kline Pharmaceuticals;

Melanoma vaccine/therapeutic - recombinant human melanoma GP100 and NY-ESO-1 antigens for therapeutic use in pre-clinical development with the National Cancer Institute (NCI);

Malaria vaccine - recombinant MSP1 protein vaccines in pre-clinical development with the National Institute of Allergy and Infectious Diseases (NIAID);

Anti-Stroke therapeutic - recombinant E-selectin antigens for tolerization of high-risk stroke patients in pre-clinical development with the National Institute of Neurological Disorders and Stroke;

Influenza VLP vaccine - recombinant human and avian influenza virus-like particle vaccines in pre-clinical development.



MediGene Projects in clinical development




TransMIDTM™ (XR311)
Indication High-grade glioma (brain cancer)
Design Modified diphtheria toxin (CRM107) conjugated to transferrin (Tf)
Status Phase III

Tariquidar (XR9576)
Indication Multi-drug resistance in cancer
Design P-glycoprotein antagonist
Status Phase II

Novel DNA Targeting Agents-Product XR11576, XR5944, XR11612
Indication Solid tumours
Design Novel mode of action
Status XR11576 and XR5944 both in Phase I XR11612 in pre-clinical testing

Indication Late stage pancreatic cancer
Design Radio-immunotherapy
Status Phase I/II

Indication Cocaine dependence
Design Therapeutic Vaccine (protein conjugate)
Status Phase II

Indication Nicotine dependence
Design Therapeutic Vaccine (protein conjugate)
Status Phase I

Indication Inflammatory and autoimmune disease; infectious disease and cancer
Design Fusion protein
Status Pre-clinical


Protein Sciences


Immune Response Corporation

Technology evaluation: NeuroVax, immune response corp




Oxford BioMedica


GenVec Inc.



General Info

New Breast Cancer Vaccine Passes First Hurdle Experimental Breast Cancer Vaccine Halts Tumors in Mice

New Vaccine for Treatment of Colorectal Cancer Shows Promise in Phase II Trial



The Diseases   The Vaccines   ThePharmaceutical Company's    VAERS   

Vaccine Ingredients   Autism   Vaccine Info    Journal Articles    Vaccine Recommendations  

 Government Information    NVICP   Links    News     HOME